As of last Friday, October 22nd, we have 419 patients in KALBITOR access and the (inaudible) 246 patients have KALBITOR placed at the treatment site. So we more than doubled the amount of patients on KALBITOR since the last quarter and had approximately an eight-fold increase over the patients in the first quarter. At nine months into KALBITOR's loss we believed we had the large HAE patient base than any other company in the HAE market at this point in their lives. Based on these positive numbers we are reaffirming our previous guidance that we will have more than 300 hundred patients with KALBITOR placed at the treatment centers by year-end. As we've indicated before building a patient base is our number priority. With this momentum going into the fourth quarter we are well poised for future success. We believe KALBITOR's adoption in the market place can be attributed to several factors.

One of which is the growing realization among HAE patients and their physicians that they need to be prepared for their next attack. Now that there is an acute an option. It has been proven to treat all attack locations; patients understand that is possible to have a more effective treatment plan in place. Furthermore reasonable market research indicates that patients would rather treat their disease acutely and prophylactically. To that end we continue to see prophylactic patients taking KALBITOR to treat near break through attacks. Regarding KALBITOR's availability world wide we have made significant progress with our global development and commercially safe strategy, as we have shared with you in the past our objective is to partner outside the U.S. with the company's committed to developing treatments for rare diseases.

Our news collaboration in Japan we chose a partner with that level of dedication. Ivana will tell you more about this after our launch update. With respect to our financials George will provide more detail later in the call and discuss note worthy highlights for the quarter. Then Bill will update you regarding our life cycle management program for KALBITOR. This involves (inaudible) work, a potential pediatric legal expansion, and additional indications for each inhibitor induced (inaudible). Finally, I'll provide an overview of our pipeline and (inaudible) to fund research program before we conclude the call.

If you liked this article you might like

Towers Watson & Co. - Analyst/Investor Day

Cresud's CEO Discusses F2Q12 Results - Earnings Call Transcript

Ocean Power Technologies Management Discusses Q1 2013 Results - Earnings Call Transcript

Microsemi Corporation - Analyst/Investor Day

Lattice Semiconductor's CEO Presents At Deutsche Bank's DbAccess 2012 Technology Conference (Transcript)